Our team is always excited to share the promising news from our sponsors of recent IITRI in vivo studies. Links below
New Sponsor Publication from NHP Inhalation Study at IITRI: Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial (Arrowhead Pharmaceuticals)
IITRI continues to support many biotech, academic institutions, and small pharma to develop and test efficacy and safety of new drugs, including for infectious disease, gene therapy, and Schedule 1 drugs and treatments. Reach out to us today to discuss your program needs!
Recent Comments